Literature DB >> 30485213

Spindle cell oncocytoma of the pituitary gland.

Alexandra M Giantini Larsen1, David J Cote1, Hasan A Zaidi1, Wenya Linda Bi1, Paul J Schmitt2, J Bryan Iorgulescu3, Michael B Miller3, Timothy R Smith1, M Beatriz Lopes4, John A Jane2, Edward R Laws1.   

Abstract

OBJECTIVE: The authors report the diagnosis, management, and outcomes of 6 cases of spindle cell oncocytoma (SCO) in an effort to guide clinical diagnosis and management of these uncommon lesions.
METHODS: This study is a retrospective review of cases involving adult patients who underwent resection of pituitary lesions at the authors' institutions between January 2000 and October 2017. The authors identified patients with histopathological confirmation of SCO and collected clinical data, including preoperative, perioperative, and postoperative management, complications, and outcomes.
RESULTS: Six patients with SCO were identified. Clinical findings at initial presentation included visual disturbances, dizziness, and headache. All patients underwent resection. Four resections were initially performed by the transsphenoidal approach, and 2 resections were performed by craniotomy at an outside institution with subsequent transsphenoidal reoperations. Neither necrosis nor increased mitotic activity was seen in the tumor samples. All samples stained positive for S100 protein and thyroid transcription factor 1 and negative for glial fibrillary acidic protein and pituitary hormones. Five of the samples stained positive for epithelial membrane antigen. The average MIB-1 index was 8.3% (range 2-17). Postoperatively, 3 of the 6 patients received further treatment for progression of residual tumor or for recurrence, 2 have stable residual tumor, and 1 has had no recurrence after gross-total resection. Two patients developed postoperative complications of transient sixth cranial nerve palsy and diplopia. There were no other complications.
CONCLUSIONS: SCO poses both a diagnostic and therapeutic challenge. These tumors are often initially misdiagnosed as nonfunctional pituitary adenomas because of their sellar location and nonspecific symptomatology. Postoperatively, SCO must also be distinguished from other neoplasms of the posterior pituitary gland through histopathological examination. Resection of SCO can be challenging, given its highly vascular and adherent nature. Long-term follow-up is critical, as the tumor is associated with higher recurrence and progression rates compared to other benign neoplasms of the sella.

Entities:  

Keywords:  CN = cranial nerve; CNS = central nervous system; EMA = epithelial membrane antigen; GFAP = glial fibrillary acidic protein; GTR = gross-total resection; OSH = outside hospital; S100 = S100 protein; SCO = spindle cell oncocytoma; TS = transsphenoidal; TTF-1 = thyroid transcription factor 1; WHO = World Health Organization; neurosurgery; pituitary surgery; spindle cell oncocytoma; transsphenoidal

Mesh:

Year:  2018        PMID: 30485213      PMCID: PMC6486883          DOI: 10.3171/2018.4.JNS18211

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  35 in total

1.  Spindle cell oncocytomas and granular cell tumors of the pituitary are variants of pituicytoma.

Authors:  Ozgur Mete; Maria Beatriz Lopes; Sylvia L Asa
Journal:  Am J Surg Pathol       Date:  2013-11       Impact factor: 6.394

2.  The 2007 Revised World Health Organization (WHO) Classification of Tumours of the Central Nervous System: newly codified entities.

Authors:  Gregory N Fuller; Bernd W Scheithauer
Journal:  Brain Pathol       Date:  2007-07       Impact factor: 6.508

3.  Spindle cell oncocytoma of the adenohypophysis: report of a case with marked cellular atypia and recurrence despite adjuvant treatment.

Authors:  O Casar Borota; B W Scheithauer; S Lyngvi Fougner; J K Hald; J Ramm-Pettersen; J Bollerslev
Journal:  Clin Neuropathol       Date:  2009 Mar-Apr       Impact factor: 1.368

Review 4.  Spindle cell oncocytoma: Report of two cases with massive bleeding and review of the literature.

Authors:  Domenico Billeci; Elisabetta Marton; Enrico Giordan; Valentina Carraro; Monica Ronzon; Sabrina Rossi
Journal:  J Clin Neurosci       Date:  2017-03-09       Impact factor: 1.961

5.  Spindle cell oncocytoma of the adenohypophysis with marked hypervascularity. Case report.

Authors:  Hironori Fujisawa; Yasuo Tohma; Naoki Muramatsu; Shinya Kida; Yasuharu Kaizaki; Hiroyasu Tamamura
Journal:  Neurol Med Chir (Tokyo)       Date:  2012       Impact factor: 1.742

Review 6.  Pituicytoma, spindle cell oncocytoma, and granular cell tumor: clarification and meta-analysis of the world literature since 1893.

Authors:  M F Covington; S S Chin; A G Osborn
Journal:  AJNR Am J Neuroradiol       Date:  2011-09-29       Impact factor: 3.825

Review 7.  Spindle cell oncocytoma of the adenohypophysis: a case report illustrating its natural history with 8-year observation and a review of the literature.

Authors:  Jessica A Rotman; Walter Kucharczyk; Galareh Zadeh; Tim-Rasmus Kiehl; Hussein Al-Ahmadi
Journal:  Clin Imaging       Date:  2014-03-15       Impact factor: 1.605

8.  Thyroid transcription factor 1 expression in sellar tumors: a histogenetic marker?

Authors:  Edward B Lee; Tarik Tihan; Bernd W Scheithauer; Paul J Zhang; Nicholas K Gonatas
Journal:  J Neuropathol Exp Neurol       Date:  2009-05       Impact factor: 3.685

9.  Spindle cell oncocytoma of the adenohypophysis in a woman: a case report and review of the literature.

Authors:  M Mlika; H Azouz; I Chelly; I Ben Saïd; H Jemel; S Haouet; M Zitouna; N Kchir
Journal:  J Med Case Rep       Date:  2011-02-14

Review 10.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

View more
  7 in total

1.  Pituitary spindle cell oncocytoma: illustrative case.

Authors:  Taha M Taka; Chen Yi Yang; Joshua N Limbo; Alvin Y Chan; Jordan Davies; Edward C Kuan; Scott G Turner; Frank P K Hsu
Journal:  J Neurosurg Case Lessons       Date:  2021-10-04

2.  Recommendation to improve the WHO classification of posterior pituitary tumors as a unique entity: evidence from a large case series.

Authors:  Nidan Qiao; Haixia Cheng; Zhaoyun Zhang; Hongying Ye; Ming Shen; Xuefei Shou; Xiaoyun Cao; Hong Chen; Xiang Zhou; Yongfei Wang; Yao Zhao
Journal:  Endocr Connect       Date:  2022-06-17       Impact factor: 3.221

3.  Surgical resection of granular cell tumor of the sellar region: three indications.

Authors:  Abdul-Kareem Ahmed; Hassan Y Dawood; David J Cote; Tejus A Bale; Umberto De Girolami; Edward R Laws; Timothy R Smith
Journal:  Pituitary       Date:  2019-12       Impact factor: 4.107

4.  The epidemiology and management patterns of pediatric pituitary tumors in the United States.

Authors:  Luz E Castellanos; Madhusmita Misra; Timothy R Smith; Edward R Laws; J Bryan Iorgulescu
Journal:  Pituitary       Date:  2021-01-12       Impact factor: 4.107

5.  Spindle cell oncocytoma of the sella turcica with anaplastic features and rapid progression in short-term follow-up: a case report with proposal of distinctive radiologic features.

Authors:  Dong Ja Kim; SangHan Lee; Mee-Seon Kim; Jeong-Hyun Hwang; Myong Hun Hahm
Journal:  J Pathol Transl Med       Date:  2021-03-09

6.  Epidemiology of common and uncommon adult pituitary tumors in the U.S. according to the 2017 World Health Organization classification.

Authors:  Luz E Castellanos; Catherine Gutierrez; Timothy Smith; Edward R Laws; J Bryan Iorgulescu
Journal:  Pituitary       Date:  2021-09-27       Impact factor: 4.107

7.  Posterior pituitary tumours: patient outcomes and determinants of disease recurrence or persistence.

Authors:  Liza Das; Kim Vaiphei; Ashutosh Rai; Chirag Kamal Ahuja; Paramjeet Singh; Ishani Mohapatra; Rajesh Chhabra; Anil Bhansali; Bishan Dass Radotra; Ashley B Grossman; Márta Korbonits; Pinaki Dutta
Journal:  Endocr Connect       Date:  2021-04       Impact factor: 3.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.